Release Date: 13/12/22 13:44 Summary: Appointment of Executive Director & CEO Samuel Smith Price Sensitive: Yes Download Document 210.49KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%